Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 28, 2022; 28(40): 5807-5817
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5807
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5807
Table 1 Main studies investigating the deleterious role of frailty, low muscle mass, sarcopenia and myosteatosis in patients undergoing pre-transplant assessment
Ref. | Patient selection | Patients, n | Sarcopenia, myosteatosis | Frailty parameters | Outcome | Results |
Lai et al[15], 2019 | Ambulatory cirrhotic patients awaiting LT | 1014 | Non applicable | LFI | Waiting list mortality | Frailty: 25%. HR = 1.82; 95%CI: 1.31-2.52; P < 0.001 |
Fozouni et al[48], 2020 | LT recipients | 241 | Non applicable | LFI | Acute cellular rejection within 3 mo post-LT | Frailty: 19%. OR = 3.3; 95%CI: 1.2-9.3; P = 0.02 |
Lai et al[47], 2022 | LT recipients | 1166 | Non applicable | LFI | LT LOS. ICU stay. Inpatient days within 3 mo post-LT. Overall survival (1-3 and 5-yr mortality) | Frailty: 21%. Prolonged LT LOS: OR = 2.00; 95%CI: 1.47-2.73. ICU stay: OR = 1.56; 95%CI: 1.12-2.14. Inpatient days within 3 mo. post-LT: OR = 1.72; 95%CI: 1.25-2.37. Overall survival: P = 0.02 |
Bhanji et al[41], 2018 | Cirrhotic patients assessed for LT | 675 | L3-MA (HU). L3-SMI | Non applicable | HE. Mortality | Sarcopenia: 36%. HE: OR = 2.42; 95%CI: 1.43-4.10; P = 0.001. Mortality: Univariate HR = 2.02; 95%CI: 1.57-2.58; P < 0.001. Multivariate: HR = 2.15; 95%CI: 1.52-3.05; P < 0.001. Myosteatosis: 52%. HE: OR = 2.25; 95%CI: 1.32-3.85; P = 0.003. Mortality: Univariate: HR = 1.45; P = 0.004; 95%CI: 1.16-2.91. Multivariate: P = 0.69 |
Van Vugt et al[42], 2016 | LT candidates/recipients | 3804. Meta-analysis | SMI. Total psoas area | Non applicable | Waiting list mortality. Post-LT mortality | Waiting list mortality: HR = 1.72; 95%CI: 0.99-3.00; P = 0.02. Post-LT mortality: HR = 1.84; 95%CI: 1.11-3.05; P = 0.05 |
Bot et al[40], 2021 | ESLD patients awaiting LT | 262 | L3-SMI (cm2/ | Non applicable | Waiting list mortality | Low SMI: HR = 2.580; 95%CI: 1.055-6.308. MA: HR = 9.124; 95%CI: 2.871-28.970 |
Czigany et al[24], 2020 | LT recipients | 225 | L3-SMI. L3-MA (HU) | Non applicable | Major morbidity. ICU stay. LT LOS | Sarcopenia: 37%. Myosteatosis: 44%. Major morbidity: OR = 2.772; 95%CI: 1.516-5.066; P = 0.001. ICU stay: 18 ± 25 vs 11 ± 21 d, P < 0.001. LT LOS: 56 ± 55 vs 33 ± 24 d, P < 0.001 |
- Citation: Goffaux A, Delorme A, Dahlqvist G, Lanthier N. Improving the prognosis before and after liver transplantation: Is muscle a game changer? World J Gastroenterol 2022; 28(40): 5807-5817
- URL: https://www.wjgnet.com/1007-9327/full/v28/i40/5807.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i40.5807